⚡️🇺🇸#TWTR WebMD and Twitter collaborate for first health content partnership
⚡️🇺🇸#MSRN Mersana Therapeutics updates updated interim data from the ovarian cancer cohort of the XMT-1536 phase 1 expansion study
⚡️🇺🇸#APOG #отчетности
Apogee Q2 Non-GAAP
EPS of $0.73 beats by $0.44; GAAP EPS of $0.67 beats by $0.38.
Revenue of $319.48M (-10.5% Y/Y) beats by $3.59M.
Operating cash flow of $85M YTD, up $68M compared to prior year.
Total backlog of $1.1B remains well above prior year level.
Outlook: The company is not providing guidance due to the continued impact of COVID-19 and related economic uncertainty. The company expects continued project delays and soft market conditions but expects revenue and earnings in the second half of fiscal 2021 to improve compared to the first half of the fiscal year.
Apogee Q2 Non-GAAP
EPS of $0.73 beats by $0.44; GAAP EPS of $0.67 beats by $0.38.
Revenue of $319.48M (-10.5% Y/Y) beats by $3.59M.
Operating cash flow of $85M YTD, up $68M compared to prior year.
Total backlog of $1.1B remains well above prior year level.
Outlook: The company is not providing guidance due to the continued impact of COVID-19 and related economic uncertainty. The company expects continued project delays and soft market conditions but expects revenue and earnings in the second half of fiscal 2021 to improve compared to the first half of the fiscal year.
💥🇺🇸#GRA W.R. Grace sees improvements in some end markets, well-positioned to capture recovery
⚡️🇺🇸#SWI SolarWinds announces integration with Servicenow service graph connector program
⚡️🇺🇸#ACN Accenture announces formation of Accenture Cloud First with $3B investment
🇺🇸#SFIX MKM Partners starts off coverage on Stitch Fix with a Neutral rating
⚡️🇺🇸#BMY Bristol Myers Squibb announces updated results from a Phase 3 clinical trial, CheckMate-214
⚡️💥🇺🇸#CKPT Checkpoint Therapeutics' cosibelimab shows encouraging action in skin cancer study
⚡️🇺🇸#CMD #отчетности
Cantel Medical Q4 Non-GAAP
EPS of $0.24 beats by $0.25; GAAP EPS of -$0.05 beats by $0.11.
Revenue of $233.4M (-2.5% Y/Y) beats by $0.85M.
Cantel Medical Q4 Non-GAAP
EPS of $0.24 beats by $0.25; GAAP EPS of -$0.05 beats by $0.11.
Revenue of $233.4M (-2.5% Y/Y) beats by $0.85M.
#MTLR
"МЕЧЕЛ" ЗАТРАТИТ В 2020 Г СВЫШЕ 1 МЛРД РУБ НА КРУПНЫЕ РЕМОНТЫ НА ОБОГАТИТЕЛЬНЫХ ФАБРИКАХ - ПРАЙМ
"МЕЧЕЛ" ЗАТРАТИТ В 2020 Г СВЫШЕ 1 МЛРД РУБ НА КРУПНЫЕ РЕМОНТЫ НА ОБОГАТИТЕЛЬНЫХ ФАБРИКАХ - ПРАЙМ